Overview

Gender

male

Fleming is board certified in clinical biochemistry. He earned a PhD in clinical pathobiology from the Medical University of South Carolina, where he also completed a postdoctoral fellowship in clinical biochemistry.

Dr Fleming has been part of the LabCorp organization since 1989, presently as vice president and director of the Department of Science and Technology and was formerly responsible for the administrative and technical operations of the Special Chemistry department at LabCorp’s Esoteric Testing laboratory. His current responsibilities include the determination of core laboratory diagnostic testing and platform decisions for LabCorp and the ongoing quality vigilance associated with all testing. These decisions incorporate improvements in workflow efficiencies through platform consolidations, cost containment strategies, and early assessment and adoption of cutting-edge technology.

Previously, Dr Fleming held an appointment as an associate professor at the Medical University of South Carolina and as a consultant to the government of Burma to upgrade the laboratory systems throughout that country. He served as member of the North Carolina Legislative Task Force on the Early Detection of Kidney Disease and on the Board of Registry. He once chaired the Clinical Chemistry Examination Committee for the American Society of Clinical Pathology..

Dr Fleming currently serves as a member of the Laboratory Working Group of the National Institutes of Health National Kidney Disease Education Program, the Laboratory Engagement Advisory Group of the National Kidney Foundation, and as an invited lecturer for the American Society of Clinical Pathologists for numerous seminars and workshops.

Dr Fleming is a fellow of the Academy of Clinical Biochemistry, a clinical scientist with the American Society of Clinical Pathology, a member of the American Association for Clinical Chemistry, and a professional member of both the American Diabetes Association and the American Heart Association.